The concordance between p19 Arf molecular perturbations and altered protein expression was 63%. However, upon comparing p19 Arf promoter perturbations (i.e. methylation of functional transcription factor binding sites and point mutations) and altered p19 Arf expression, the concordance was 86%, suggesting a mechanism for changes in protein expression in some tumors. There was an absence of a mutually exclusive relationship between disruption of p53 and p19 Arf , since the concordance was 62%. Similarly, no evidence was found of inverse relationships between perturbation of p16 Ink4a and p19 Arf (43% concordance) or p16 Ink4a and p53 (37% concordance), suggesting that inactivation of these genes occurs independently and provides evidence that, although these genes may participate in cooperative cellular pathways, they also have functions in independent pathways that are important in mouse lung tumorigenesis.
Introduction
Inactivation of the INK4a/ARF locus is one of the most frequently observed molecular lesions in human cancers (1, 2) . The locus encodes two tumor suppressor proteins, p16 INK4a and p14 ARF , which are homologous to mouse p16 Ink4a and p19 Arf , respectively. p16 Ink4a and p19 Arf have separate promoters and produce different transcripts; the p16 Ink4a transcript is formed by exons 1α, 2 and 3, and the p19 Arf transcript is formed by exons 1β, 2 and 3 (2-5). Although exons 2 and 3 are common to both transcripts, they are read in different frames. p16 Ink4a is a cell-cycle inhibitor and modulator of senescence (6) , and inhibits the kinase activity of cyclin dependent kinases (Cdk*) 4 and/or Cdk6, preventing the phosphorylation of retinoblastoma protein (pRB) and subsequent passing of cells from G 1 into S phase. The p19 Arf protein is a negative regulator of the p53-destabilizing oncogene, mdm2 (7) .
The expression of p16 Ink4a and p19 Arf is normally low in adult mouse tissues (8, 9 ) but stresses such as oncogenic ras, can induce the expression of p16 Ink4a and p19 Arf , resulting in cell-cycle arrest (10) (11) (12) (13) . Release of the transcription factor E2F-1 by hypophosphorylated pRB can induce p19 Arf (14) , thereby linking the p16 Ink4a -pRB pathway to the p19 Arf -p53 pathway.
The Ink4a/Arf gene locus can be inactivated by three mechanisms, which often work in combination. Loss of heterozygosity (LOH) of alleles is the most common mechanism reported for both human and experimental animal cancers (15) (16) (17) (18) (19) (20) (21) . Mutations in exons 1α, 1β and 2 are rare and occur predominantly in melanomas (22) . Finally, promoter silencing by hypermethylation of cytosine-guanine (CpG) sites in p16 INK4a and/or p14 ARF occurs in human tumors (23) (24) (25) (26) (27) , and p16 Ink4a promoter hypermethylation is an important inactivation mechanism in experimental animals (28, 29) . Little is known about the involvement of murine p19 Arf promoter hypermethylation in lung tumorigenesis, as this region was only recently characterized (30, 31) .
We have used an AC3F1 (A/JϫC3H/HeJ) mouse model to investigate the pulmonary carcinogenic mechanisms of the fungal toxin, aflatoxin B 1 (AFB 1 ). Consistent with the known DNA-damaging effects of AFB 1 , all of the lung tumors examined contained point mutations at guanine residues in the first exon of K-ras, with almost all occurring in codon 12 (32) . We also found that, unlike other mouse lung tumors, p53 mutations occurred at a high frequency in the AFB 1 -induced tumors. However, the specific point mutations were variable and were heterogeneously distributed throughout the tumors, suggesting relatively late occurrence in tumor development (33) .
Several studies have examined the relationship between the p16 INK4a -pRB pathway and the p14 ARF -p53 pathway and the proteins therein. It is assumed that because p14 ARF acts upstream from p53, disruption of only one of p14 ARF or p53 is required for tumorigenesis (34) . This mutually exclusive relationship has been observed in resectable non-small cell lung carcinomas (NSCLC) (35) and human glioblastomas (36) ; however, in NSCLCs analyzed by Sanchez-Cespedes et al. (37) and high-grade neuroendocrine lung tumors (38) , alterations in both p14 ARF and p53 were observed. The absence of an inverse correlation between p14 ARF and p53 genetic perturbations suggests that these genes also function in independent pathways (27) . Furthermore, the concomitant mutation of both p16 INK4a and p53, indicative of inactivation of both p16 INK4a -pRB and the p14 ARF -p53 pathways, illustrates collaboration between the two pathways in tumor development.
The primary objective of this study was to characterize the role of Ink4a/Arf in AFB 1 -induced mouse lung tumorigenesis. Because of the unusual involvement of p53 in the AFB 1 -induced tumors and its close association with p16 Ink4a and p19 Arf , it was possible to assess the coincidence of inactivation of these genes. This is the first study to show that inactivation of p19 Arf occurs in mouse lung tumor development. Furthermore, although p53, p16 Ink4a and p19 Arf function within the 123 p16 Ink4a -pRB and p19 Arf -p53 pathways, our results suggest that these genes have roles in independent pathways that are important in mouse lung tumorigenesis.
Materials and methods

Mouse lung tumor induction and DNA isolation
Female, 5-7-week-old AC3F1 mice were obtained from The Jackson Laboratory, Bar Harbor, ME. Animals were dosed (150 mg/kg i.p. divided into 24 doses over 8 weeks) and killed 6-14 months after dosing, as described by Donnelly et al. (32) . A portion of each tumor was frozen in liquid nitrogen and stored at -70°C, and the remainder was fixed in 10% neutral-buffered formalin. DNA was obtained from frozen whole lung tumors by proteinase digestion followed by phenol-chloroform-isoamyl alcohol extraction and ethanol precipitation. tissues were deparaffinized in xylene and hydrated through a series of aqueous ethanol solutions to 1ϫ Automation Buffer™ (AB) (Biomeda, Foster City, CA). Endogenous peroxidase was blocked using 3% H 2 O 2 for 15 min and epitope retrieval was performed using a Decloaker (Biocare Medical, Walnut Creek, CA). Normal donkey serum (1.5%) (Jackson Immnoresearch Laboratories, West Grove, PA) was applied to the sections for 1 h at room temperature and endogenous avidin and biotin were blocked using an Avidin Biotin Blocking Kit (Vector Laboratories). Application of the p19 Arf primary antibody was applied for 1 h at room temperature and normal goat serum (Jackson Immunoresearch Labs, West Grove, PA) was used as the negative control in place of the primary antibody. The bound primary antibody was visualized by streptavidin-biotin-peroxidase detection using the Santa Cruz Goat ABC Staining Kit (Santa Cruz Biotechnology), according to the manufacturer's instructions and using the liquid Dako DAB Chromagen (Dako Corporation, Carpinteria, CA) as the color-developing agent. Sections were counterstained with Harris hematoxylin (Harelco, Gibbstown, NJ), dehydrated through a series of aqueous ethanol solutions to xylene, and coverslipped with Permount (Fisher Scientific, Norcross, GA). Five day postnatal mouse lung tissues from untreated mice that express p19 Arf were used as positive controls to verify staining.
Immunohistochemical analysis of p16 Ink4a expression was not possible as unexpectedly, several antibodies (28, 39, 40) produced various degrees of positive staining in brain, colon and spleen tissues from a p16 Ink4a knockout mouse (41), suggesting possible non-specific staining.
LOH analysis of lung tumor DNA
The microsatellites D4Mit77 (35 cM from the chromosome 4 centromere) (Research Genetics, Huntsville, AL) and Mts1 (2172 bp upstream of the p16 Ink4a translation start site) (28, 42) were selected to determine LOH due to their proximity to the Ink4a/Arf locus (42 cM from the chromosome 4 centromere) (28) . PCR amplification of a microsatellite marker, was performed with 5Ј 33 P-forward primers and 50 ng genomic DNA. Equal volumes of the diluted PCR products and gel-loading buffer (89% formamide, 0.1% bromophenol blue, 0.1% xylene cyanol FF, 10 mM EDTA) were mixed and heated at 95°C for 5 min. Samples were then cooled on ice prior to loading on an 8% denaturing polyacrylamide gel containing 8 M urea. Samples were electrophoresed at 35 W for 1-2 h and gels dried for 1 h at 80°C prior to autoradiography. The gel was also exposed to an Imaging Screen-K (Bio-Rad, Hercules, CA), and band intensities were visualized and quantified on a STORM 820 PhosphoImager (Molecular Dynamics, Sunnyvale, CA). To determine LOH, bands representing each allele were quantified and analyzed as described by Hegi et al. (19) . To determine LOH, a normalized ratio for each tumor was calculated by taking the ratio of the alleles (i.e. C3H/HeJ: A/J to determine loss of the A/J allele; A/J:C3H/HeJ to determine loss of the C3H/HeJ allele) of the tumor and dividing it by the ratio of the alleles (in the same manner as above) of the non-tumor sample. If the normalized ratio was Ͼ1.5, then loss of the allele was considered to have occurred.
PCR amplification and SSCP analysis of p16 Ink4a and p19 Arf
Exons 1α, 1β and 2 of the Ink4a/Arf gene locus were amplified by PCR using primers and PCR conditions modified after Zhuang et al. (43) . For SSCP analysis of Ink4a/Arf exons 1α, 1β and 2 from whole lung tumors, PCR products from the first reaction were subjected to a second amplification which incorporated [α-33 P]dATP (PerkinElmer Life Sciences, Boston, MA). Amplification was carried out for 20 cycles. Four microliters of the α-33 Plabeled PCR products were diluted with 50 µl 0.1% SDS and 10 mM EDTA. Equal volumes of the diluted PCR products and gel-loading buffer [89% formamide, 0.1% bromophenol blue, 0.1% xylene cyanol FF, 10 mM EDTA (pH 8.0)] were mixed and heated at 95°C for 5 min. Samples were then cooled on ice prior to loading on a 6% non-denaturing polyacrylamide gel containing 10% glycerol. Samples were electrophoresed with TBE [Trisborate with EDTA (pH 8.0)] buffer at 55 W for 7 h at 4°C, dried and autoradiographed as described above.
Bisulfite modification and PCR amplification of lung tumor DNA Methylation of both p16 Ink4a and p19 Arf promoters was determined using sodium bisulfite genomic sequencing (28, 44, 45) . The bisulfite-modified DNA was amplified as described by Patel et al. (28) , using Platium Taq polymerase (Invitrogen Life Technologies, Burlington, ON). For amplification of the p16 Ink4a promoter (GenBank accession no. U4018), primers 20FM and 11RM were used for the outer PCR reaction and 42FM and 11RM were used for the inner reaction.
Amplification of the p19 Arf promoter (GenBank accession no. AF120108) employed primers 1FM (5Ј-GGGTGTAGTTATTGTTAGGGGG-3Ј) and 1RM (5Ј-AAATATAATTCTCTCCCAAAAAA-3Ј), and 2.4 mM MgCl 2 for the outer amplification for 25 cycles (denaturation at 94°C for 1 min, annealing at 53°C for 35 s and extension at 72°C for 1 min). The inner reaction employed primers 1FM and 2RM (5Ј-AAAAAACCCTCTCTTAAAATAAA-3Ј), 2.4 mM MgCl 2 and 30 cycles (denaturation at 94°C for 1 min, annealing at 63°C for 35 s and extension at 72°C for 1 min plus 1 s/cycle). PCR products were electrophoresed in a 2.0% low melting point agarose gel and visualized using ethidium bromide. The desired bands were excised and purified with a QIAquick Gel Extraction Kit (Qiagen, Mississauga, ON) and resuspended in 50 ml of distilled water.
Direct DNA sequencing of bisulfite-modified DNA DNA from 2.0 µl of the bisulfite-modified PCR amplified DNA-containing solution was sequenced with the Thermo Sequenase radiolabeled terminator cycle sequencing kit (Amersham Pharmacia Biotech, Cleveland, OH) and the 11RM PCR primer (for p16 Ink4a ) and 2RM and/or 2RMI (5Ј-CAACCCATCTTTACTCCA-3Ј, for p19 Arf ). Samples were then electrophoresed at 55 W for 1-2.5 h in an 8% polyacrylamide denaturing gel containing 7 M urea. The gel was dried and autoradiographed as described above. The methylation status of individual CpG sites was scored visually. Re-amplification and re-sequencing of 10 tumor DNA samples from the original template confirmed reproducibility of the methylation analysis.
Results
Tumor induction
A total of 19 mice were killed between 6 and 12 months after the completion of dosing, in order to assess tumor development. At 6 and 7 months, occasional hyperplasias and small adenomas were observed. By 9.5 months, numerous adenomas were seen, as well as a few carcinomas arising within adenomas. At 12 months, multiple adenomas and carcinomas, which were large enough to excise and freeze were observed. The remaining 43 mice were killed at 14 months. Sixty (97%) of the AFB 1 -treated mice possessed lung tumors at the time of death, and in the 43 mice killed at 14 months, there were, on average, 7.23 lung tumors per mouse. Of the AFB 1 -induced tumours that were frozen, 76 (40 adenomas and 36 carcinomas) were collected and utilized in this study (Table I) . Immunohistochemistry Expression of p19 Arf is low in adult mouse tissues and increases in response to oncogenic stimuli (e.g. activated K-ras) (10) (11) (12) (13) . In the present study, absent or decreased nuclear expression (in 80-100% of cells) of p19 Arf was observed in 41 of 71 (58%) tumor tissue sections (Table I ). The decreased expression of p19 Arf was not significantly different between adenomas and adenocarcinomas (Fisher's exact test, P ϭ 0.09) and the pattern of staining was homogeneous in all tumors. LOH and mutation analyses of lung tumor DNA LOH of D4Mit77 occurred in 14 of 74 (19%) tumors; the A/J allele was lost in 10 tumors and both alleles were lost in four (Table I, Figure 1 ). Loss of Mts1 alleles occurred in 11 of 74 tumors (15%). Of the 11 tumors, four had lost the A/J allele, five had lost the C3H/HeJ allele, and one had lost both (Table I, Figure 1 ). Tumors 20, 27, 64 and 70 had very low band intensities of both alleles compared with alleles of the non-tumor DNA sample and were believed to have loss of both alleles. Furthermore, tumors that appeared to have loss of both parental alleles in one microsatellite marker had at least one allele lost at the other marker. Exon 5 of p53 from these tumors was successfully amplified using primers described in Tam et al. (33) , confirming that the lack of detection of microsatellite PCR products was not attributable to poor DNA quality. The frequency of LOH in adenomas versus adenocarcinomas was not significantly different at D4Mit77 (Fisher's exact test, P ϭ 1.0) or Mts1 (P ϭ 0.33).
SSCP analysis of exons 1α, 1β and 2 of p16 Ink4a and p19 Arf revealed no point mutations in the 74 tumors analyzed. Two polymorphisms in exons 1α and 2, which affect only the p16 Ink4a gene, were confirmed between the A/J and C3H/HeJ strains (43, 46) . The p16 Ink4a variants differ at amino acids 18 (histidine or proline) and 51 (valine or isoleucine) and the less functional proline/isoleucine variant contributes to susceptibility to lung tumorigenesis (46) . As expected, the non-tumor DNA sample was heterozygous at both codon 18 (CAT and CCT) and codon 51 (GTA and ATA). Visual scoring of the sequencing autoradiographs of the polymorphic sites in tumors 23 and 44 indicated loss of the A/J allele, consistent with the loss of the A/J allele of D4Mit77 in the same tumors.
Methylation of the p16 Ink4a and p19 Arf promoters in mouse lung tumors
The p16 Ink4a promoter-exon 1α region contains a CpG island that is frequently methylated in human and rodent tumors (28, 29, (47) (48) (49) (50) (51) (52) . CpG sites -1 to -7 relative to the translation start codon in exon 1α of the mouse p16 Ink4a gene (Table II) appear to constitute the most frequently methylated region of the p16 Ink4a promoter resulting in altered transcription (28) , and were therefore the focus for this study. Direct sequencing of sodium bisulfite-modified DNA revealed at least partial methylation of the p16 Ink4a promoter in 51 of 61 (84%) of the tumors (Table II, Figure 2 ). According to visual scoring, 160 of 211 (76%) CpG sites had Ͻ50% methylation (partial methylation), while 51 of 211 (24%) had Ͼ50% methylation. It has been reported that decreased expression of p16 Ink4a correlates well with the percentage of CpG sites methylated (i.e. density-dependent hypermethylation model; Ͼ25% of a The methylated sites are reported with reference to the translation start codon. The methylation status of each site is: M ജ50% methylated CpG site; P, 0-50% methylated CpG site; U, unmethylated CpG site. b The numbers in parentheses represent the location of each CpG site and are given in base pairs upstream of the translational start site. c Indicates the location of a putative transcription factor binding site identified using MatInspector (82) . d Sample 75 is the non-tumor DNA sample. CpG sites) (50) , and the percent methylation at individual CpG sites (i.e. ജ50%) (28) . In the AFB 1 -induced tumors, Ͼ50% methylation at 25% or more of the CpG sites occurred in 10 of 61 (16%) tumors. The occurrence of hypermethylation was not statistically significantly different between adenomas and adenocarcinomas (Fisher's exact test, P ϭ 0.08); however, the frequency of methylated CpG sites increases as tumors progress from adenomas to adenocarcinomas (Fisher's exact test, P Ͻ 0.05). The murine p19 Arf promoter contains a 1 kb CpG island which is immediately upstream of exon 1β (30) . This region contains transcription factor binding sites and consensus sequences at the following locations relative to the translation start codon: a DMP1/Ets site, position -181 to -189; a CTCF (for CCCTC-binding factor) zinc-finger binding site between positions -199 to -235; E2F consensus sequences, positions -189 to -195 and -257 to -266 (antisense strand) and Sp1 consensus sequence sites at positions -59 to -65, -105 to -111 and -139 to -144 (Table III) (30, 53) . Since methylation status of the murine p19 Arf promoter CpG island has not been characterized in lung tumors, a region that has been reported previously to be sufficient for basal p19 Arf promoter activity (54) and includes CpG sites numbered -1 to -41 (nucleotides -7 to -299 relative to the translation start codon, respectively), was analyzed (Table III) . At least partial methylation was present in 43 of 49 (88%) tumors analyzed (Tables I and III, Figure 3 ). Sufficient tumor DNA was not available to assess promoter methylation in the remaining tumors. In the nontumor DNA sample and in almost all tumors, CpG sites -38 to -41 were hypermethylated (Table III, Figure 3 ). These sites were considered to be Alu-like sequences and were not included in analyses since it has been shown that methylation of these sites occurs in normal tissue and tumor cell lines, regardless of gene expression status (55) . A total of 21 of 43 (49%) tumors had functional transcription factor binding sites or consensus sequences hypermethylated (Tables I and III) . Two promoter-region point mutations were identified and confirmed by sequencing non-bisulfite treated DNA; tumor 45 contained a G→T transversion at position -132 relative to the translation start codon and tumor 57 had a C→A transversion at position -107, which is a CpG site within an Sp1 transcription factor consensus sequence (Table I) .
Correlation between p19 Arf molecular alterations and protein expression
At most, 25% of p19 Arf promoter CpG sites were at least partially methylated in tumors. The concordance between the presence of hypermethylation and decreased/absence of protein expression or absence of hypermethylation and normal protein expression, was 63% and did not change when LOH and point mutations were also considered (i.e. presence of molecular alterations and decreased/absent protein expression or absence of molecular alterations and normal protein expression). When methylation of functional transcription factor binding sites and the presence of point mutations in the p19 Arf promoter were compared with protein expression the concordance was 86%.
Relationship between p16 Ink4a , p19 Arf and p53
In general, normal expression of both p53 and p19 Arf is required for cell-cycle regulation (56, 57) . Alterations in expression of these proteins are good indicators that the pathways in which the proteins function are compromised. Furthermore, it was determined previously that there was a high correlation between positive staining for p53 and the presence of p53 mutations in the AFB 1 -induced tumors (33) . For these reasons, immunohistochemical staining results for p53 and p19 Arf were used to calculate concordance values. p53 perturbations occurred in 79% of the tumors and p19 Arf perturbations in 58% (Table I) ; however, the concordance (tumors with p53 overexpression and altered p19 Arf expression or absence of p53 overexpression and normal p19 Arf expression) between p53 mutation and p19 Arf perturbations was 62%. Thus, p53 and p19 Arf perturbations were not mutually exclusive (Fisher's exact test, P ϭ 0.07).
As a result of the unavailability of p16 Ink4a immunohistochemical data, molecular data for p16 Ink4a was used to calculate concordance rates. According to previous studies, the occurrence of LOH and/or 50% hypermethylation at 25% or more of CpG sites of p16 Ink4a will result in inactivation of the gene. Therefore, the concordance between p16 Ink4a molecular perturbations and p19 Arf protein expression (i.e. tumors with p16 Ink4a mutations and altered p19 Arf or absence of the p16 Ink4a mutations and normal p19 Arf ) was assessed and found to be 43%. Inactivation of p16 Ink4a and p19 Arf did not occur concomitantly (Fisher's exact test, P ϭ 0.42). Furthermore, the concordance between p53 and p16 Ink4a (tumors with both p53 and p16 Ink4a perturbations or absence of both p53 and p16 Ink4a perturbations) was 37%, demonstrating that inactivation of both genes is not necessary for tumorigenesis within these tumors (Fisher's exact test, P ϭ 0.31).
Discussion
The discovery that the Ink4a/Arf locus is inactivated by LOH and/or hypermethylation of CpG sites within promoter regions of both p16 Ink4a and p19 Arf and is corroborated by p19 Arf immunohistochemical data, suggests that this locus has a role in AFB 1 -induced mouse lung tumorigenesis. LOH plays a relatively minor role in inactivating this gene locus since the frequency of LOH (30%) was low in these tumors when compared with tumors induced by other carcinogens (Ͼ50% LOH) (19, 21, 58, 59) . In contrast to the observation that LOH occurred in methylene chloride-induced B6C3F1 adenocarcinomas but not in adenomas (19) , frequency of LOH did not differ between AFB 1 -induced adenomas and adenocarcinomas, suggesting that LOH occurs prior to or early during adenoma 
development. Similar to the findings by Herzog et al., there was a bias for deletion of the normal A/J allele (14 of 22 tumors with loss of alleles) and retention of the intact C3H/ HeJ allele, which encodes the less active form of p16 Ink4a . These findings provide additional evidence that the Ink4a/Arf locus is a pulmonary adenoma resistance/susceptibility locus in these tumors (46) . Consistent with low or zero frequency in mouse lung tumors induced by other agents (42, 60, 61) , point mutations were not present in the Ink4a/Arf exons of AFB 1 -induced tumors.
The fact that decreased expression of p19 Arf was not significantly different between adenomas and adenocarcinomas suggests that p19 Arf perturbations also occur prior to or early during adenoma development. A similar result was found for mutation of p53 (33) and suggests that inactivation of the p19 Arf -p53 pathway and other pathways involving p53 may be required for tumor progression.
Hypermethylation of CpG sites in promoter regions is being revealed as one of the most frequent mechanisms of loss of gene function in cancer (62) . To assess methylation within tumors, bisulfite gene sequencing was employed instead of the commonly used methylation-specific PCR (MS-PCR), as comparisons between the degree of methylation at individual CpG sites and the percent methylation within tumors to gene seen earlier in tumor progression. This is supported by the fact that p16 Ink4a promoter methylation occurs not only in mouse lung adenocarcinomas but also in adenomas, which is consistent with results from other species and tumor types, and indicates that p16 Ink4a methylation is a relatively early event in tumorigenesis (64) . Interestingly, the frequency of CpG site methylation increased as tumors progressed from adenoma to adenocarcinoma (Table II) .
Although p14 ARF promoter methylation status has been examined in human cancers (26, 27) , this is the first analysis of the homolog in mouse lung tumors. In contrast to a lack of methylation in normal lung DNA, hypermethylation was present in 43 of 49 (88%) tumors analyzed, which differs from γ-radiation-induced mouse primary lymphomas, in which hypermethylation of the region occurred at low frequency (30) . Unlike p16 Ink4a , where decreased gene expression corresponds to density-dependent methylation, the concordance between hypermethylation of CpG sites and protein expression was low (63%). However, when hypermethylation of transcription factor binding sites was compared with protein expression, the concordance was 86%. Six of seven (86%) tumors with methylated DMP1, CTCF and/or E2F transcription factor binding sites, had decreased p19 Arf expression. A functional DMP1 transcription factor-binding site is located in the p19 Arf promoter and there exists evidence that binding of E2F is also important in gene activation (30) . In addition, a CTCF functional transcription factor-binding site has been discovered in the murine p19 Arf promoter (53) . Altered expression of the insulin-like growth factor-II (Igf2) gene due to methylation of CpG sites within CTCF binding sites has been observed (65), and our results provide evidence that methylation of these sites can affect p19 Arf expression. Unexpectedly, methylation of a functional DMP1 site and loss of the A/J allele did not affect p19 Arf protein expression in tumor 34 (Table I) . Since 129 p53 also was not affected (Table I) (33) , it appears that alterations in the p19 Arf -p53 pathway are not involved in this tumor.
Furthermore, the presence of p19 Arf promoter point mutations in two tumors also coincided with decreased expression of the protein. The presence of these mutations may have altered the conformation of the chromatin, thus preventing RNA transcriptional machinery from binding. Although not all changes in p19 Arf expression can be explained from the data, it appears that alterations in this promoter, either by hypermethylation of transcription factor binding sites or by the presence of point mutations, is one mechanism by which transcription of p19 Arf is affected in the AFB 1 -induced tumors.
Previously, K-ras exon 1 mutations were observed in all of the AFB 1 -induced tumors examined in this study, with the majority of point mutations involving the first and second bases of codon 12 (32) . Different types of K-ras mutations have been reported to influence the carcinogenic potential of a tumor (66) ; however, a correlation between specific K-ras mutations and perturbations of p16 Ink4a and p19 Arf was not observed (data not shown).
In the mammalian genome, unmethylated CpG islands are often surrounded by regions of DNA called methylation centers and it is believed that methylation spreads from these centers (67, 68) . The high frequency of methylation at the 3Ј end of both the p16 Ink4a and p19 Arf CpG islands suggests that a possible methylation center may exist downstream from both the respective CpG islands (Tables II and III) (55, 67) . Interestingly, consensus sequences identified as potential Sp1 transcription factor binding sites are present in both p16 Ink4a and p19 Arf promoters (28, 30) (Tables II and III) and Sp1 sites protect against methylation spreading from flanking regions of a CpG island (55, (69) (70) (71) . CpG sites within the p16 Ink4a promoter were more frequently methylated than were those in the p19 Arf promoter in the AFB 1 -induced tumors. This may be due to the greater number of Sp1 sites present in the p19 Arf promoter, which may govern the relative propensity of the two promoters to become hypermethylated (25) . The presence of multiple Sp1 sites at the 3Ј end of the p19 Arf CpG island suggests a barrier between the CpG island and a downstream methylation center (55, 67) (Table III) .
Hypermethylation of CpG sites -38 to -41 in the p19 Arf promoter was present in the DNA from the non-tumor sample and almost all tumors (Figure 3 ). These sequences could potentially represent interspersed nuclear transposable elements such as Alu sequences, which are frequently methylated, and can be distributed near coding regions or promoters (72) (73) (74) . Alu repeats within the CpG island regions of E-cad and VHL genes are extensively methylated in normal tissue and tumor cell lines, regardless of gene expression status or the tissue of origin (55) . For this reason, the methylation status of CpG sites -38 to -41 was not included in the concordance analyses.
Collectively, LOH, point mutations and hypermethylation have roles in inactivating p19 Arf ; however, alternative mechanisms for inactivation of the gene must exist since there are tumors in which p19 Arf expression was lost or reduced without identified perturbation of the gene. For example, overexpression of the bmi-1 oncogene can repress the transcriptional activity of p16 Ink4a and p19 Arf promoters (75) , and could potentially play a role in mouse lung tumorigenesis.
p19 Arf functions to activate p53 by preventing its degradation, and it has been hypothesized that alterations in only one of these two genes are required for disruption of this pathway in tumor development (34) . Since, unlike most mouse lung tumors, p53 mutations were present in the AFB 1 -induced tumors (33), we had the unique opportunity to determine the relationship between these two genes and their products. There was a lack of an inverse correlation between perturbation of p53 and p19 Arf suggesting that both proteins can function independently in AFB 1 -induced mouse lung tumors. Consistent with this conclusion are the observations that various tumors (e.g. lymphomas, fibrosarcomas, epidermal carcinomas) from p19 Arf -null mice also have p53 mutations (76) and that p19 Arf can induce a broad spectrum of genes [e.g. B-cell translocation gene (BTG) family], that are not induced by p53 but act to arrest cell proliferation (77) . Furthermore, in human lung cancers, 50% of NSCLC tumors harboring p53 mutations also had p19 Arf inactivation (37), and no relationship was determined between p53 and p19 Arf in high-grade neuroendocrine lung tumors (38) .
In the AFB 1 -induced tumors, inactivation of both p16 Ink4a -pRB and p19 Arf -p53 pathways was observed with co-inactivation of p16 Ink4a and p19 Arf (23% of tumors) and co-perturbation of p16 Ink4a and p53 (60% of tumors). In primary human central nervous system lymphomas, both pathways are inactivated in approximately half of tumors (78) and it has been shown in various mouse tumors (e.g. lung carcinomas and lymphomas), that deficiency of p16 Ink4a and p53 cooperate in mouse tumorigenesis (79) . Recently, it was discovered that Mdm2 is able to bind to and inhibit pRB (80); therefore, if p19 Arf is inactivated, there will be an increase in Mdm2, and subsequent inhibition of the p16 Ink4a -pRB pathway. This may explain the observation that p16 Ink4a is not co-perturbed with p53 or p19 Arf in all tumors; if Mdm2 inactivates pRB, then inactivation of p16 Ink4a might not be necessary.
Overall, our study demonstrates that perturbations in the Ink4a/Arf gene locus occur in AFB 1 -induced mouse lung tumors. Alterations in p16 Ink4a occurred by promoter hypermethylation and by loss of alleles, which is consistent with the observation in a variety of human and animal cancers that these perturbations affect protein expression (28, 29, (47) (48) (49) 58, 81) . De-regulation of p19 Arf expression also occurred by promoter methylation and loss of alleles; however, unlike p16 Ink4a , hypermethylation of transcription factor binding sites rather than density-dependent methylation, and the presence of promoter point mutations resulted in altered protein expression. As the Ink4a/Arf and p53 tumor suppressor gene loci are the most frequently altered genes in tumorigenesis and are involved in overlapping pathways, we have assessed the involvement of these genes within individual tumors. The inactivation of p16 Ink4a and p19 Arf tended to occur independently and inactivation of p53 and p19 Arf was not mutually exclusive and is consistent with the view that the inactivation of both p16 Ink4a -pRB and p19 Arf -p53 cell-cycle regulatory pathways and alternative pathways is dependent on p16 Ink4a p19 Arf , and p53 can contribute to tumor development.
